Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Slides:

Advertisements

Similar presentations

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.

Advertisements

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1. TP is highly expressed in myeloma.

Fig. 6. Sh-lantibiotics are commonly found on healthy human skin and synergize with a host AMP. Sh-lantibiotics are commonly found on healthy human skin.

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Intravenous delivery of reovirus to primary and secondary brain tumors

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 4. Specific versus nonspecific NP accumulation.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Macrophage-specific ablation of Vegfa in PyMT implant tumors blocks blood vessel permeability and tumor cell intravasation at the TMEM. A and C, immunofluorescence.

Fig. 1. Aberrant JNK pathway activation in mouse models of ALS and in spinal cord tissue from patients with sporadic ALS. Aberrant JNK pathway activation.

Fig. 2 In vitro assessment of hESC-RPE cell sheets.

Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.

Fig. 5. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic composition. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic.

Fig. 5. MMP-7 expression in human liver, EHBD, and gallbladder.

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Fig. 2. Circulating VEGF in GCA patients up-regulates microvascular endothelial Jagged1. Circulating VEGF in GCA patients up-regulates microvascular endothelial.

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Fig. 7. NPs accumulate at sites of vascular obstruction.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.

Fig. 1 Effect of preinfection β7Hi CD45RA−CD4+ T cell frequency on HIV acquisition risk in CAPRISA 004 study. Effect of preinfection β7Hi CD45RA−CD4+ T.

PAAND is driven by local inflammasome activation and IL-1β production

Fig. 3. TKI sensitivity assessed by the MANO method.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4 Analysis of ISO response in vitro in neonatal cardiomyocytes.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Fig. 1 CSPG4 is expressed in GBM specimens and GBM-NS and associated with more aggressive disease. CSPG4 is expressed in GBM specimens and GBM-NS and associated.

Fig. 4. Acute lung injury in miR-223−/y mice.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 7 Analysis of the bacterial nidus within tissue abscesses by MALDI IMS demonstrates a paucity of calprotectin signal. Analysis of the bacterial nidus.

Fig. 6 Photoreceptor cell survival in the RCS rat retina after transplantation with hESC-RPE cell sheets. Photoreceptor cell survival in the RCS rat retina.

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

JAK2 knockdown abrogates tumorsphere expansion after chemotherapy

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 6 Combination therapy with LVSOD2 and LVshCTGF preserves flap volume and reduces fibrosis after RT. Combination therapy with LVSOD2 and LVshCTGF preserves.

Fig. 4 Lentiviral transgene expression penetrates tissue and provides durable effects in vivo. Lentiviral transgene expression penetrates tissue and provides.

Fig. 6. Comparison of Plk4 with Sas-6 localization

Fig. 1 ZIKV RNA in blood and tissues.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia by Zainul S. Hasanali, Bikramajit Singh Saroya, August Stuart, Sara.

Fig. 6. Sh-lantibiotics are commonly found on healthy human skin and synergize with a host AMP. Sh-lantibiotics are commonly found on healthy human skin.

Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Fig. 5. Paclitaxel promotes breast cancer cell dissemination and metastasis in a MENA-dependent manner. Paclitaxel promotes breast cancer cell dissemination.

Presentation transcript:

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. (A) Individual TMEM scores of 20 patients before and after receiving NAC, which included weekly paclitaxel (80 mg/m2 × 12 consecutive weeks) followed sequentially by dose-dense AC chemotherapy [doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) every 2 weeks × four cycles, plus pegfilgrastim (6 mg, subcutaneously) on day 2 of each cycle]. The patients did not receive tamoxifen. Red line: TMEM high-risk cutoff point according to (5). (B) Representative images of TMEM triple-stain IHC in patients #3 and #7 in the pre-NAC core biopsies (upper panels) and post-NAC resected tumors (lower panels). Scale bar, 50 μm. (C) Mean TMEM scores in the 20 human breast cancers shown in (A), before and after receiving NAC, Wilcoxon test. (D) Representative images of MENAINV protein expression, as visualized by MENAINV IF and DAPI in a patient receiving NAC. Scale bar, 100 μm. (E) Quantification of the MENAINV-positive area in pre- and post-NAC patient samples. Assay performed in only seven of the patients shown in (A) because of limited availability of pre-NAC biopsy material for the remaining 13 patients. Mann-Whitney U test. (F) MENAINV gene expression, as assessed by real-time RT-PCR, in FNA biopsies taken from five breast cancer patients before and after 2 weeks of receiving NAC with paclitaxel. George S. Karagiannis et al., Sci Transl Med 2017;9:eaan0026 Published by AAAS